Claims for Patent: 8,003,375

Summary for Patent: 8,003,375

Title:	Qualitative differential screening
Abstract:	The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA\'s derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA\'s derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.
Inventor(s):	Schweighoffer; Fabien (Vincennes, FR), Bracco; Laurent (Paris, FR), Tocque; Bruno (Courbevoie, FR)
Assignee:	ExonHit Therapeutics S.A. (Paris, FR)
Application Number:	12/622,364
Patent Claims:	1. A device for identifying the presence or absence of at least a first differentially spliced product of a first gene or RNA, wherein said device comprises a solid support material and single-stranded oligonucleotides of between 5 and 100 nucleotides in length attached to said support material, wherein at least one of said oligonucleotides has a length of 25-100 nucleotides, wherein said oligonucleotides comprise at least a first and a second oligonucleotide molecule arranged serially on the support material, wherein said first oligonucleotide molecule comprises a first sequence that is complementary to and specific for a first exon or exon-exon or exon-intron junction region of said first gene or RNA, and wherein said first sequence corresponds to a region of variability in at least one product of said first gene or RNA due to differential splicing, and wherein said second oligonucleotide molecule comprises a second sequence that is complementary to and specific for a second exon or exon-exon or exon-intron junction region of said first gene or RNA, and wherein said second sequence corresponds to a region of variability in at least one product of said first gene or RNA due to differential splicing, said device allowing, when contacted with a diverse population of nucleic acid molecules prepared from a biological sample under conditions allowing hybridisation to occur, the determination of the presence or absence of said first differentially spliced product relative to at least a second differentially spliced product of said first gene or RNA. 2. The device of claim 1, wherein said first and second oligonucleotide molecules are available from a compilation of published sequences or sequence information from at least one database. 3. The device of claim 1, wherein the support material is selected from the group consisting of a filter, a membrane and a chip. 4. The device of claim 1, wherein said single-stranded oligonucleotides are RNA molecules. 5. The device of claim 1, wherein said single-stranded oligonucleotides comprise oligonucleotides of less than 50 nucleotides in length. 6. The device of claim 5, wherein said single-stranded oligonucleotides comprise oligonucleotides of 25 nucleotides in length. 7. The device of claim 1, wherein said single-stranded oligonucleotides are specific for alternative splicings representative of a cell or tissue in a given pathological condition. 8. The device of claim 7, wherein said single-stranded oligonucleotides are specific for alternative splicings representative of a tumor cell or tissue. 9. The device of claim 7, wherein said single-stranded oligonucleotides are specific for alternative splicings representative of a cell or tissue undergoing apoptosis. 10. The device of claim 7, wherein said device further comprises one or more single-stranded oligonucleotides specific for a product of said first gene or RNA expressed under normal conditions. 11. The device of claim 1, where said device is useful to evaluate the toxicity of a compound or treatment to a cell, tissue, or organism by determining the presence or absence of said first differentially spliced product in a sample treated with said compound or treatment. 12. The device of claim 1, where said device is useful to evaluate the therapeutic efficacy of a compound to a cell, tissue, or organism by determining the presence or absence of said first differentially spliced product in a sample from said cell, tissue, or organism. 13. The device of claim 1, where said device is useful to evaluate the responsiveness of a subject to a compound or treatment by determining the presence or absence of said first differentially spliced product in a sample from said subject exposed to said compound or treatment. 14. The device of claim 1, wherein said device allows the determination of the presence or absence of two or more differentially spliced products of said first gene or RNA. 15. The device of claim 1, wherein said device allows the determination of the presence or absence of one or more differentially spliced products of two or more genes or RNAs. 16. The device of claim 15, wherein said device further comprises one or more single-stranded oligonucleotides specific for a product of said two or more genes or RNAs expressed under normal conditions. 17. The device of claim 1, wherein said single-stranded oligonucleotides are DNA molecules. 18. The device of claim 1, wherein said first sequence of said first oligonucleotide molecule is complementary to and specific for said first exon-exon or exon-intron junction region of said first gene or RNA, and wherein said second sequence of said second oligonucleotide molecule is complementary to and specific for said second exon-exon or exon-intron junction region of said first gene or RNA. 19. The device of claim 1, wherein said device consists essentially of single-stranded, differentially spliced oligonucleotides. 20. The device of claim 1, wherein each of said single-stranded oligonucleotides are directly attached to said support material. 21. The device of claim 1, wherein said second sequence of said second oligonucleotide molecule is complementary to and specific for said second exon-exon or exon-intron junction region of said first gene or RNA. 22. The device of claim 1 further comprising a third oligonucleotide molecule comprising a third sequence that is complementary to and specific for a second gene or RNA, wherein said third sequence corresponds to a region of variability in at least one product of said second gene or RNA due to differential splicing, said device allowing the determination of the presence or absence of a differentially spliced product of said second gene or RNA. 23. The device of claim 1, wherein said single-stranded oligonucleotides comprise oligonucleotides of 25 to 100 nucleotides in length. 24. The device of claim 1, wherein said devices comprises at least one single-stranded oligonucleotide having a length of 25 nucleotides.

Details for Patent 8,003,375

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-03-11
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-03-11
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-03-11